Alan Duy Khiem Le, NP
Nurse Practitioner · Alameda
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 5 years
- Graduated 2021
Offices
1 location
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Alan Duy Khiem Le’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$22,505
Medicare paid this office $22,505 for 44 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 33 | $9,307 | $109 |
| Long return visit (40+ min) | 35 | $9,240 | $123 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,317 | $73 |
| Psychiatric diagnostic evaluation with medical services | 12 | $766 | $64 |
Who their Medicare patients are
44 Original Medicare patients in 2024. Average age 51 · Women 46% · Also on Medicaid 100% · Health risk score 1.04. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 34% · Diabetes 32%.
The office billed $104,278, Medicare allowed $32,716 and paid $22,505; for 215 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 44 | 215 | 51 | 1.04 | $104,278 | $22,505 |
| 2023 | 32 | 152 | 53 | 1.37 | $56,634 | $12,040 |
| 2022 | 21 | 45 | 51 | 0.95 | $14,241 | $4,772 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 18 | $4,199 | $123 |
| Return visit (30+ min) | 16 | $1,605 | $80 |
Drugs they prescribed that Part D paid
$869,967
Pharmacies billed $869,967 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,135) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,862 generic and 273 brand-name prescriptions · $869,967 in drug cost · 163 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Austedo Xr | 24 | $220,074 | $9,170 |
| Invega Sustenna | 63 | $184,068 | $2,922 |
| Uzedy | 29 | $82,855 | $2,857 |
| Lybalvi | 45 | $70,134 | $1,559 |
| Vraylar | 35 | $54,522 | $1,558 |
See all 51 drugs
| Austedo Xr | 24 | $220,074 | $9,170 |
| Invega Sustenna | 63 | $184,068 | $2,922 |
| Uzedy | 29 | $82,855 | $2,857 |
| Lybalvi | 45 | $70,134 | $1,559 |
| Vraylar | 35 | $54,522 | $1,558 |
| Clozapine Odt | 61 | $50,813 | $833 |
| Abilify Maintena | 14 | $35,096 | $2,507 |
| Paliperidone Er | 18 | $8,838 | $491 |
| Clozapine | 105 | $7,408 | $71 |
| Trintellix | 13 | $6,602 | $508 |
| Risperidone Odt | 20 | $6,442 | $322 |
| Aripiprazole | 67 | $4,965 | $74 |
| Haloperidol | 73 | $2,797 | $38 |
| Dexmethylphenidate Hcl Er | 12 | $2,774 | $231 |
| Divalproex | 134 | $2,758 | $21 |
| Divalproex Sodium Er | 43 | $2,466 | $57 |
| Haloperidol Decanoate | 40 | $2,252 | $56 |
| Perphenazine | 27 | $1,892 | $70 |
| Olanzapine Odt | 56 | $1,712 | $31 |
| Benztropine Mesylate | 133 | $1,516 | $11 |
| Quetiapine | 72 | $1,115 | $15 |
| Glycopyrrolate | 12 | $842 | $70 |
| Olanzapine | 76 | $829 | $11 |
| Clomipramine | 24 | $785 | $33 |
| Trazodone | 99 | $651 | $7 |
| Valproic Acid | 20 | $608 | $30 |
| Sertraline | 105 | $508 | $5 |
| Naltrexone | 18 | $482 | $27 |
| Gabapentin | 61 | $461 | $8 |
| Risperidone | 102 | $450 | $4 |
| Hydroxyzine | 19 | $412 | $22 |
| Buspirone | 32 | $396 | $12 |
| Lurasidone | 13 | $381 | $29 |
| Hydroxyzine Pamoate | 25 | $347 | $14 |
| Venlafaxine Hcl Er | 19 | $335 | $18 |
| Lithium Carbonate | 28 | $331 | $12 |
| Valproic Acid | 12 | $287 | $24 |
| Mirtazapine | 35 | $236 | $7 |
| Bupropion Xl | 17 | $219 | $13 |
| Fluoxetine | 39 | $162 | $4 |
| Propranolol | 18 | $157 | $9 |
| Amantadine | 22 | $156 | $7 |
| Levothyroxine | 18 | $155 | $9 |
| Simvastatin | 14 | $115 | $8 |
| Metformin | 15 | $114 | $8 |
| Lisinopril | 12 | $100 | $8 |
| Topiramate | 16 | $71 | $4 |
| Clonidine | 12 | $65 | $5 |
| Metoprolol | 12 | $63 | $5 |
| Paroxetine | 16 | $41 | $3 |
| Citalopram Hbr | 12 | $39 | $3 |
Year by year
| 2024 | 2,135 | 69 | 0% (0) | 13% | $869,967 |
| 2023 | 1,502 | 64 | 0% (0) | 13% | $644,181 |
| 2022 | 360 | 35 | 0% (0) | 11% | $127,262 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 37 drugs
| Invega Sustenna | 99 | $293,228 | $2,962 |
| Abilify Maintena | 13 | $39,757 | $3,058 |
| Lybalvi | 21 | $32,552 | $1,550 |
| Aripiprazole | 55 | $15,580 | $283 |
| Lurasidone | 15 | $14,448 | $963 |
| Paliperidone Er | 20 | $12,121 | $606 |
| Clozapine Odt | 11 | $8,043 | $731 |
| Divalproex | 91 | $4,420 | $49 |
| Olanzapine | 69 | $3,302 | $48 |
| Olanzapine Odt | 43 | $3,186 | $74 |
| Risperidone Odt | 17 | $2,921 | $172 |
| Divalproex Sodium Er | 29 | $2,766 | $95 |
| Clozapine | 30 | $2,685 | $90 |
| Quetiapine | 61 | $2,278 | $37 |
| Risperidone | 96 | $1,998 | $21 |
| Hydroxyzine Pamoate | 36 | $1,839 | $51 |
| Haloperidol Decanoate | 23 | $1,601 | $70 |
| Gabapentin | 41 | $1,323 | $32 |
| Amantadine | 39 | $1,281 | $33 |
| Perphenazine | 17 | $1,206 | $71 |
| Benztropine Mesylate | 79 | $1,157 | $15 |
| Valproic Acid | 31 | $967 | $31 |
| Trazodone | 61 | $914 | $15 |
| Mirtazapine | 42 | $908 | $22 |
| Haloperidol | 23 | $762 | $33 |
| Sertraline | 75 | $752 | $10 |
| Valproic Acid | 13 | $703 | $54 |
| Venlafaxine Hcl Er | 11 | $475 | $43 |
| Naltrexone | 13 | $472 | $36 |
| Hydroxyzine | 21 | $372 | $18 |
| Buspirone | 22 | $333 | $15 |
| Fluoxetine | 37 | $255 | $7 |
| Propranolol | 15 | $245 | $16 |
| Prazosin | 11 | $214 | $19 |
| Lamotrigine | 11 | $212 | $19 |
| Topiramate | 15 | $196 | $13 |
| Paroxetine | 23 | $165 | $7 |
2022: 14 drugs
| Abilify Maintena | 14 | $33,606 | $2,400 |
| Invega Sustenna | 11 | $32,674 | $2,970 |
| Aristada | 11 | $30,787 | $2,799 |
| Aripiprazole | 30 | $3,711 | $124 |
| Divalproex | 25 | $1,324 | $53 |
| Duloxetine | 13 | $1,283 | $99 |
| Olanzapine | 27 | $891 | $33 |
| Amantadine | 11 | $430 | $39 |
| Trazodone | 23 | $369 | $16 |
| Benztropine Mesylate | 21 | $357 | $17 |
| Risperidone | 14 | $328 | $23 |
| Quetiapine | 15 | $271 | $18 |
| Hydroxyzine | 13 | $208 | $16 |
| Sertraline | 17 | $166 | $10 |
Money from drug and device companies
$4,421 in 2025
| 2025 | 9 | 115 | $740 | $4,421 |
| 2024 | 5 | 62 | None | $2,571 |
| 2023 | 4 | 31 | None | $1,408 |
| 2022 | 2 | 38 | None | $1,236 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Cobenfy | $1,660 | 16 payments
|
| Alkermes | Aristada | $540 | 29 payments
|
| Teva Pharmaceuticals USA | Uzedy | $442 | 8 payments
|
| Neurocrine BioSciences | Ingrezza | $422 | 13 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $385 | 12 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $313 | 13 payments
|
See all 115 published payments
| Abbvie | Meals · 2025-12-18 | Vraylar | $16 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-18 | Caplyta | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-16 | Cobenfy | $20 |
| Alkermes | Meals · 2025-12-15 | Aristada | $13 |
| Alkermes | Meals · 2025-12-12 | Aristada | $29 |
| Otsuka America Pharmaceutical | Meals · 2025-12-10 | Abilify Maintena | $26 |
| Otsuka America Pharmaceutical | Meals · 2025-12-10 | Abilify Maintena | $3 |
| Neurocrine BioSciences | Meals · 2025-12-10 | Ingrezza | $17 |
| Axsome Therapeutics | Meals · 2025-12-05 | Auvelity | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-12-05 | Uzedy | $35 |
| Otsuka America Pharmaceutical | Meals · 2025-12-03 | Rexulti | $26 |
| Alkermes | Meals · 2025-12-02 | Aristada | $10 |
| Teva Pharmaceuticals USA | Meals · 2025-12-02 | Uzedy | $122 |
| Abbvie | Meals · 2025-11-26 | Vraylar | $6 |
| Neurocrine BioSciences | Meals · 2025-11-24 | Ingrezza | $16 |
| Janssen Pharmaceuticals | Meals · 2025-11-19 | Invega Sustenna | $18 |
| Alkermes | Meals · 2025-11-19 | Aristada | $15 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-14 | Caplyta | $31 |
| Teva Pharmaceuticals USA | Meals · 2025-11-06 | Uzedy | $22 |
| Alkermes | Meals · 2025-10-22 | Aristada | $9 |
| Otsuka America Pharmaceutical | Meals · 2025-10-22 | Abilify Maintena | $35 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-21 | Cobenfy | $14 |
| Abbvie | Meals · 2025-10-21 | Vraylar | $35 |
| Teva Pharmaceuticals USA | Meals · 2025-10-21 | Uzedy | $40 |
| Alkermes | Meals · 2025-10-20 | Aristada | $7 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-17 | Cobenfy | $146 |
| Abbvie | Meals · 2025-10-15 | Vraylar | $10 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-15 | Caplyta | $24 |
| Axsome Therapeutics | Meals · 2025-10-09 | Auvelity | $20 |
| Otsuka America Pharmaceutical | Meals · 2025-10-07 | Rexulti | $28 |
| Alkermes | Meals · 2025-10-06 | Aristada | $13 |
| Abbvie | Meals · 2025-09-30 | Vraylar | $11 |
| Alkermes | Meals · 2025-09-30 | Lybalvi | $28 |
| Alkermes | Meals · 2025-09-26 | Aristada | $17 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-24 | Caplyta | $26 |
| Abbvie | Meals · 2025-09-16 | Vraylar | $12 |
| Axsome Therapeutics | Meals · 2025-09-11 | Auvelity | $116 |
| Alkermes | Meals · 2025-09-10 | Aristada | $19 |
| Alkermes | Meals · 2025-09-08 | Aristada | $19 |
| Otsuka America Pharmaceutical | Meals · 2025-09-02 | Rexulti | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-20 | Cobenfy | $119 |
| Neurocrine BioSciences | Meals · 2025-08-18 | Ingrezza | $17 |
| Axsome Therapeutics | Meals · 2025-08-16 | Auvelity | $22 |
| Alkermes | Meals · 2025-08-13 | Aristada | $8 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-06 | Caplyta | $35 |
| Neurocrine BioSciences | Meals · 2025-08-05 | Ingrezza | $25 |
| Alkermes | Meals · 2025-07-31 | Lybalvi | $118 |
| Alkermes | Meals · 2025-07-29 | Aristada | $8 |
| Alkermes | Meals · 2025-07-22 | Aristada | $10 |
| Abbvie | Meals · 2025-07-21 | Vraylar | $11 |
| Alkermes | Meals · 2025-07-16 | Aristada | $6 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-07-15 | Caplyta | $35 |
| Neurocrine BioSciences | Meals · 2025-07-14 | Ingrezza | $26 |
| Otsuka America Pharmaceutical | Meals · 2025-07-11 | Abilify Maintena | $29 |
| Abbvie | Meals · 2025-07-09 | Vraylar | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-03 | Cobenfy | $109 |
| Alkermes | Meals · 2025-07-01 | Aristada | $15 |
| Otsuka America Pharmaceutical | Meals · 2025-07-01 | Abilify Asimtufii | $29 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-27 | Caplyta | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-26 | Cobenfy | $20 |
| Alkermes | Meals · 2025-06-24 | Aristada | $18 |
| Neurocrine BioSciences | Meals · 2025-06-23 | Ingrezza | $30 |
| Janssen Pharmaceuticals | Meals · 2025-06-18 | Invega Sustenna | $149 |
| Axsome Therapeutics | Meals · 2025-06-18 | Auvelity | $31 |
| Alkermes | Meals · 2025-06-16 | Aristada | $29 |
| Abbvie | Meals · 2025-06-11 | Vraylar | $13 |
| Teva Pharmaceuticals USA | Meals · 2025-06-11 | Uzedy | $23 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-06-04 | None | $48 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-29 | None | $740 |
| Teva Pharmaceuticals USA | Meals · 2025-05-29 | Uzedy | $41 |
| Teva Pharmaceuticals USA | Meals · 2025-05-22 | Uzedy | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-21 | Cobenfy | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-05-21 | Abilify Maintena | $30 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-05-14 | Caplyta | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-10 | None | $65 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-10 | None | $30 |
| Alkermes | Meals · 2025-05-09 | Aristada | $14 |
| Alkermes | Meals · 2025-05-08 | Aristada | $13 |
| Neurocrine BioSciences | Meals · 2025-05-07 | Ingrezza | $133 |
| Otsuka America Pharmaceutical | Meals · 2025-04-30 | Abilify Maintena | $131 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-29 | Caplyta | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-22 | Cobenfy | $17 |
| Alkermes | Meals · 2025-04-22 | Aristada | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-17 | Cobenfy | $68 |
| Alkermes | Meals · 2025-04-17 | Aristada | $28 |
| Axsome Therapeutics | Meals · 2025-04-17 | Auvelity | $34 |
| Otsuka America Pharmaceutical | Meals · 2025-04-16 | Abilify Maintena | $7 |
| Otsuka America Pharmaceutical | Meals · 2025-04-15 | Abilify Maintena | $18 |
| Alkermes | Meals · 2025-04-10 | Aristada | $14 |
| Abbvie | Meals · 2025-04-09 | Vraylar | $16 |
| Neurocrine BioSciences | Meals · 2025-04-08 | Ingrezza | $32 |
| Axsome Therapeutics | Meals · 2025-04-01 | Auvelity | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-20 | Cobenfy | $98 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-17 | Caplyta | $2 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-17 | Caplyta | $31 |
| Abbvie | Meals · 2025-03-14 | Vraylar | $13 |
| Alkermes | Meals · 2025-03-12 | Aristada | $16 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-06 | Cobenfy | $17 |
| Neurocrine BioSciences | Meals · 2025-02-28 | Ingrezza | $27 |
| Abbvie | Meals · 2025-02-26 | Vraylar | $16 |
| Alkermes | Meals · 2025-02-26 | Aristada | $5 |
| Alkermes | Meals · 2025-02-21 | Aristada | $13 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-21 | Caplyta | $22 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-21 | Caplyta | $6 |
| Abbvie | Meals · 2025-02-20 | Vraylar | $15 |
| Teva Pharmaceuticals USA | Meals · 2025-02-20 | Uzedy | $125 |
| Neurocrine BioSciences | Meals · 2025-02-14 | Ingrezza | $21 |
| Neurocrine BioSciences | Meals · 2025-02-04 | Ingrezza | $28 |
| Abbvie | Meals · 2025-01-29 | Vraylar | $14 |
| Alkermes | Meals · 2025-01-29 | Aristada | $10 |
| Abbvie | Meals · 2025-01-16 | Vraylar | $11 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-15 | Cobenfy | $125 |
| Neurocrine BioSciences | Meals · 2025-01-14 | Ingrezza | $21 |
| Neurocrine BioSciences | Meals · 2025-01-13 | Ingrezza | $29 |
| Alkermes | Meals · 2025-01-06 | Aristada | $23 |
See earlier years (2024, 2023, 2022)
2024: $2,571
| Alkermes | Aristada | $689 | 23 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $635 | 7 payments
|
| Abbvie | Vraylar | $492 | 15 payments
|
| Teva Pharmaceuticals USA | Uzedy | $418 | 7 payments
|
| Neurocrine Biosciences | Ingrezza | $337 | 10 payments
|
2023: $1,408
| Alkermes | Aristada | $489 | 18 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $323 | 3 payments
|
| Teva Pharmaceuticals USA | Uzedy | $319 | 7 payments
|
| Abbvie | Vraylar | $276 | 3 payments
|
2022: $1,236
| Sunovion Pharmaceuticals | Latuda | $842 | 33 payments
|
| Alkermes | Aristada | $394 | 5 payments
|
Professional record
- NPI
- 1891356671
- Licence
- CA 95020360, CA 95183228
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X); Federal specialty code 163WP0809X (163WP0809X)
- Mailing address
- 425 E Santa Clara St, San Jose, CA, 95113
- NPI first listed
- 2019-06-24
- NPI last updated
- 2022-10-10
- NPI record certified
- 2022-10-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 298 Bernal Rd, San Jose, CA, 95119